Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16552327 | 1.00 | PLG (0.47) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL16964802 | 0.84 | HTR1A (0.43) | LMNAMEN1KMT2AHTR1ARAB9A | |
| SCHEMBL10082604 | 0.84 | HTT (0.37) | LMNABACE1BACE2RXRARXRB | |
| SCHEMBL17145362 | 0.84 | SMN1; SMN2 (0.38) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL23476597 | 0.84 | SMN1; SMN2 (0.38) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL24829512 | 0.82 | HTR1A (0.35) | LMNABACE1BACE2RXRARXRB | |
| SCHEMBL4594540 | 0.81 | BACE1 (0.38) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL159817 | 0.80 | LMNA (0.46) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL890390 | 0.80 | LMNA (0.46) | PLGPLATLMNABACE1BACE2 | |
| SCHEMBL24939702 | 0.80 | LMNA (0.42) | PLGPLATLMNABACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896506-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2018-02-20 | — | — | US | claimed |
| US-20150314016-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-05 | — | — | US | claimed |
| US-20140335107-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-11-13 | — | — | US | claimed |
| US-20250270304-A1 | ANTI-ACTIVIN ANTIBODIES AND METHODS OF USING THE SAME | PHENOMIC AI (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-4577250-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577578-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250085287-A1 | METHODS FOR DETECTION OF MEMBRANE BOUND GLYPICAN-3 | ADICET THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. | 2025-02-13 | — | — | US | disclosed |
| US-20240309088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12053524-B2 | Anti-podocalyxin antibodies and methods of using the same | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2024-08-06 | — | — | US | disclosed |
| US-20140106374-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8617559-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENETECH, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-8466260-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130089555-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2414395-A1 | ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | Genentech, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414399-A1 | ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010120561-A1 | ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2010114940-A1 | ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | DLK1, DBNL, DVL3 | PLG 2861/4885PLAT 4406/4885LMNA 4122/4885 |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | DLK1, CD2BP2, IGLV6-57 | PLG 2252/4885PLAT 3874/4885LMNA 3510/4885 |
| US-20250270304-A1 | ANTI-ACTIVIN ANTIBODIES AND METHODS OF USING THE SAME | INHA, ACVR1, ACVR2A | PLG 755/4885PLAT 846/4885LMNA 209/4885 |
| US-20240309088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | PLG 3055/4885PLAT 3902/4885LMNA 3047/4885 |
| US-20250085287-A1 | METHODS FOR DETECTION OF MEMBRANE BOUND GLYPICAN-3 | LGALS3, LGALS3BP, CD47 | PLG 2109/4885PLAT 2088/4885LMNA 1410/4885 |
| US-20140335107-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | PLG 3055/4885PLAT 3902/4885LMNA 3047/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | PLG 784/4885PLAT 1125/4885LMNA 3206/4885 |
| US-20130089555-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | PLG 784/4885PLAT 1125/4885LMNA 3206/4885 |
| US-20150314016-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | PLG 3055/4885PLAT 3902/4885LMNA 3047/4885 |
| US-12053524-B2 | Anti-podocalyxin antibodies and methods of using the same | SDC1, SDC4, SDCBP | PLG 387/4885PLAT 360/4885LMNA 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.